| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 660 | 2013 |
| GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer PDP Pharoah, YY Tsai, SJ Ramus, CM Phelan, EL Goode, K Lawrenson, ... Nature genetics 45 (4), 362-370, 2013 | 428 | 2013 |
| Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment V Rojas, KM Hirshfield, S Ganesan, L Rodriguez-Rodriguez International journal of molecular sciences 17 (12), 2113, 2016 | 303 | 2016 |
| Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium CM Olsen, CM Nagle, DC Whiteman, R Ness, CL Pearce, MC Pike, ... Endocrine-related cancer 20 (2), 251-262, 2013 | 290 | 2013 |
| The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer KE Miletti-González, S Chen, N Muthukumaran, GN Saglimbeni, X Wu, ... Cancer research 65 (15), 6660-6667, 2005 | 272 | 2005 |
| Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies W Sieh, S Salvador, V McGuire, RP Weber, KL Terry, MA Rossing, ... International journal of epidemiology 42 (2), 579-589, 2013 | 229 | 2013 |
| Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug V Shah, O Taratula, OB Garbuzenko, OR Taratula, ... Clinical Cancer Research 19 (22), 6193-6204, 2013 | 201 | 2013 |
| Immune activation and benefit from avelumab in EBV-positive gastric cancer A Panda, JM Mehnert, KM Hirshfield, G Riedlinger, S Damare, ... JNCI: Journal of the National Cancer Institute 110 (3), 316-320, 2018 | 196 | 2018 |
| Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer H Shen, BL Fridley, H Song, K Lawrenson, JM Cunningham, SJ Ramus, ... Nature communications 4 (1), 1628, 2013 | 184 | 2013 |
| Requirements for strand transfer between internal regions of heteropolymer templates by human immunodeficiency virus reverse transcriptase JJ DeStefano, LM Mallaber, L Rodriguez-Rodriguez, PJ Fay, RA Bambara Journal of virology 66 (11), 6370-6378, 1992 | 177 | 1992 |
| Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium CM Nagle, SC Dixon, A Jensen, SK Kjaer, F Modugno, A DeFazio, ... British journal of cancer 113 (5), 817-826, 2015 | 168 | 2015 |
| Nanotechnology approaches for personalized treatment of multidrug resistant cancers T Minko, L Rodriguez-Rodriguez, V Pozharov Advanced drug delivery reviews 65 (13-14), 1880-1895, 2013 | 167 | 2013 |
| First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors MN Stein, JR Bertino, HL Kaufman, T Mayer, R Moss, A Silk, N Chan, ... Clinical cancer research 23 (15), 4163-4169, 2017 | 154 | 2017 |
| Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21. 31 J Permuth-Wey, K Lawrenson, HC Shen, A Velkova, JP Tyrer, Z Chen, ... Nature communications 4 (1), 1627, 2013 | 142 | 2013 |
| Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element KE Miletti-González, K Murphy, MN Kumaran, AK Ravindranath, ... Journal of Biological Chemistry 287 (23), 18995-19007, 2012 | 140 | 2012 |
| Identifying microRNA/mRNA dysregulations in ovarian cancer GD Miles, M Seiler, L Rodriguez, G Rajagopal, G Bhanot BMC research notes 5, 1-10, 2012 | 131 | 2012 |
| Novel chemotherapy approaches for cervical cancer S Movva, L Rodriguez, H Arias‐Pulido, C Verschraegen Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 116 | 2009 |
| Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study EV Bandera, M King, U Chandran, LE Paddock, L Rodriguez-Rodriguez, ... BMC women's health 11, 1-9, 2011 | 111 | 2011 |
| RET rearrangements are actionable alterations in breast cancer BS Paratala, JH Chung, CB Williams, B Yilmazel, W Petrosky, K Williams, ... Nature communications 9 (1), 4821, 2018 | 106 | 2018 |
| Racial/ethnic disparities in ovarian cancer treatment and survival EV Bandera, VS Lee, L Rodriguez-Rodriguez, CB Powell, LH Kushi Clinical cancer research 22 (23), 5909-5914, 2016 | 95 | 2016 |
Elisa V. BanderaRutgers Cancer Institute of New JerseyVerified email at rutgers.edu
